- cafead Nov 13, 2021 at 10:02: PM
via Despite the controversy surrounding the approval of Biogen’s Alzheimer’s drug Aduhelm (aducanumab), the company announced new data that shows the medication reduces amyloid plaque and significantly lowers plasma p-tau181, a biomarker of the hallmark tau tangles in Alzheimer’s disease.
article source
article source